Group A-beta Hemolytic Streptococci에 의한 소아 인두편도염에 있어서 Cefprozil의 항균력과 임상적 및 세균학적 효과에 관한 연구

Clinical and Bacteriologic Efficacy of Cefprozil on Pharyngitis and Pharyngotonsilitis caused by Group A Beta Hemolytic Streptococci in Children

  • 김민우 (경희대학교병원 소아과) ;
  • 안영민 (강남병원 소아과) ;
  • 장성희 (강남병원 소아과) ;
  • 마상혁 (마산 파티마병원 소아과) ;
  • 안병문 (성애병원 소아과) ;
  • 김종덕 (원광대학교병원 소아과) ;
  • 이종국 (인제대학교 일산백병원 소아과) ;
  • 김미란 (한림대학교 한강성심병원 소아과) ;
  • 장진근 (한일병원 소아과) ;
  • 박진영 (성균관대학교 강북삼성병원 소아과) ;
  • 배종우 (경희대학교병원 소아과) ;
  • 차성호 (경희대학교병원 소아과)
  • Kim, Min-Woo (Department of Pediatrics, College of Medicine, Kyung-Hee University) ;
  • Ahn, Young-Min (Department of Pediatrics, Kang-Nam General Hospital) ;
  • Jang, Seong-Hee (Department of Pediatrics, Kang-Nam General Hospital) ;
  • Ma, Sang-Hyuk (Department of Pediatrics, Fatima Hospital, Masan) ;
  • Ahn, Byung-Moon (Department of Pediatrics, Sung-Ae General Hospital) ;
  • Kim, Jong-Duk (Department of Pediatrics, College of Medicinel, Won-Kwang University) ;
  • Lee, Jong-Kook (Department of Pediatrics, College of Medicine, Inje University, Ilsan Paik Hospital) ;
  • Kim, Mi-Lan (Department of Pediatrics, College of Medicine, Hallym University, Hangang Sacred Heart Hospital) ;
  • Chang, Jin-Kun (Department of Pediatrics, Han-Il General Hospital) ;
  • Park, Jin-Young (Department of Pediatrics, College of Medicine, Sung Kyun Kwan University, Kang-Buk Samsung Medical Center) ;
  • Bae, Jong-Woo (Department of Pediatrics, College of Medicine, Kyung-Hee University) ;
  • Cha, Sung-Ho (Department of Pediatrics, College of Medicine, Kyung-Hee University)
  • 발행 : 2001.11.30

초록

최근 소아의 인두염 및 인두편도염에서 EM-resistant group A streptococci가 15~40%까지 보고가 되고 있으며, 같은 계통의 macrolide제제들의 대한 내성도 점차 증가하고 있는 양상이 나타나고 있다. 따라서 세균성 인두편도염이 의심되는 환아의 치료에 있어서 경구용 항생제를 선택할 때는 항생제에 대한 내성과 경제성 및 환아의 순응도를 고려하여 항생제를 선택하여야 하겠다.

Objective : To determine the clinical and bacteriologic efficacy and safety of Cefprozil in acute pharyngitis and pharyngotonsilitis caused by Group A beta hemolytic streptococci in pediatric patients. Methods : Any patient of 3 to 14 age who visited the hospitals enrolled in this study with the signs and symptoms of pharyngitis or pharyngotonsilitis since July, 2000 to March, 2001, was taken throat culture and given Cefprozil(15 mg/kg/day, in two divided doses) for 10 days. 138 patients of whom showed positive culture results were followed up for the signs and symptoms during the treatment to determine clinical efficacy. Any undesirable effect was reported to determine the safety of the drug. Follow up cultures were done at the end of the study and bacteriologic efficacy was determined. Results : 138 of 256 patients who visited the hospitals with the signs and symptoms of pharyngitis or pharyngotonsilitis showed positive growth on throat culture. Mean age of the patients was $6.1{\pm}2.5$ and males and females were equally numbered. 129 of them complained fever on the first visit and 112(86.6%) of them were improved at the end of the study. Cervical lymphadenitis was seen in 58 patients and 44(75.9%) of them improved at the end of the study. Exudative pharyngitis was seen in 96 patients and 81(84.3%) of them improved. The overall clinical effcacy based on this results showed that 110(79.7%) of the patients were cured and 17(12.3%) of them improved. On the cultures and bacteriologic efficacy, 24.6% of them showed documented eradication after treatment and 62.3% of them showed presumptive eradication. Sensitivity test was done by agar dilution method and Cefprozil showed 100% sensitivity. Erythromycin, Clarithromycin and azithromycin showed 87%, 85.6 %, 90.6% sensitivity, respectively. Conclusion : Cefprozil is proved to be effective in controlling group A streptococcal pharyngitis and pharyngotonsilitis in children and showed good sensitivity. Cefprozil can be used as an effective oral cephalosporin in the patients showing penicillin hypersensitivity or patients who other drugs have failed.

키워드